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• 64 years old previously relatively fit and healthy female 
• History of chronic constipation, gingivitis, anosmia
• Develops tremor, bradykinesia, voice changes, rigid facial expression, 
stooped posture, loss of swinging of left arm, small cramped writing, 
intermittent dystonia on hands and feet    
• Diagnosed with Parkinson’s disease!
What is Parkinson’s 
Disease? 
Parkinson disease (PD) is a 
chronic progressive 
neurodegenerative disease of 
the nervous system 
characterized by the cardinal 
features of rigidity, 
bradykinesia, tremor and 
postural instability. 
Categories
1. Parkinsonism: a group of 
disorders with Basal Ganglia 
dysfunction
2. PD or idiopathic 
Parkinsonism: The most 
common form
3. Secondary Parkinsonism: 
Viruses, toxins, drugs, 
tumors 
4. Parkinsonism plus 
syndromes: conditions that 
mimic PD, symptoms caused 
by some other 
neurodegenerative diseases
Etiology 
• The mechanisms of PD remain elusive 
• Several genes identified including SNCA, PARKIN, DJ-1, PINK-1, and 
LRRK2 whose mutations are responsible for rare forms of Parkinson’s 
disease. 
• oxidative stress, mitochondrial and proteseomal dysfunction and 
inflammatory system involvement 
• ? Autoimmune disease 
Signs and symptoms
Tremor
Subtle decrease in dexterity




Decreased sense of smell
Symptoms of autonomic dysfunction (eg, constipation, sweating 
abnormalities, sexual dysfunction, seborrheic dermatitis)




PD is a clinical diagnosis
No laboratory biomarkers exist for the condition
Findings on routine (MRI) and (CT) scan are 
unremarkable
MRI is useful to exclude strokes, tumors, multi-
infarct state, hydrocephalus, and the lesions of 
Wilson disease.
PET and DaT scans
Treatment
Symptomatic drug therapy
Levodopa/carbidopa: The gold standard of symptomatic 
treatment
Monoamine oxidase (MAO)–B inhibitors
Other dopamine agonists (eg, ropinirole, pramipexole)
Anticholinergic agents (eg, trihexyphenidyl, 
benztropine)
Treatment for non-motor symptoms
Sildenafil citrate (Viagra): For erectile dysfunction
Polyethylene glycol: For constipation
Modafinil: For excessive daytime somnolence
Methylphenidate: For fatigue (potential for abuse and 
addiction)
Deep brain stimulation
Continuing Case I 
Investigations 
• FBC, U&E, LFT, Bone Profile, CRP: Normal 
• MRI: Normal 
• Stool comprehensive test: Candida overgrowth, low beneficial 
bacteria
• Urine organic and amino acids: high benzoic acid, arabinase, 
Citramalic Acid, Phenylacetic Acid (PAA), α-Hydroxyisobutyric Acid, 
Pyroglutamic Acid
• Toxicity: PCB, pesticides, mercury, aluminum 
Treatment 
• Nutrition: LCHF/ altered with ketogenic diet 
• Exercise
• Optimizing gut flora 
• Treating candida overgrowth 
• Detoxification 
• Optimizing methylation pathway 
• Supplements ( glutathione precursors, antioxidants, anti-inflammatories) 
• Low dose naltrexone 
• Bioresonance & PEMFR 
• Non-laser light therapy 
• HBOT x 40 sessions 
Unified Parkinson’s Disease Rating 
Scale
At the time of diagnosis in 2012 2018 
I. Mentation, Behavior and Mood
• Intellectual Impairment





Sustained depression with vegetative
symptoms (insomnia, poor appetite, 
loss of interest) 





















Moderately slow & small mostly legible
Can cut most foods with some difficulty




Mild difficulty, no swing left arm 












Left leg-only when anxious
Occasional 
Unified Parkinson’s Disease Rating 
Scale




Tremor at Rest 










Masked face, loss of facial express
Moderate in amplitude & present 
most of the time
Slight; present with action




Frequently unable to arise without 
help
Moderately stooped posture
Short steps with shuffles 
Impaired














Unified Parkinson’s Disease Rating 
Scale
At the time of diagnosis in 2012 2018
Dyskinesia Daily None 
Early Morning Dystonia Daily None
Insomnia Severe Resolved
In summary: 
6 years after diagnosis of PD
• Not on any PD medication 
• Disease not progressing 
• Significant improvement with complete resolution of majority of the symptoms  
Case II
53 years old male, CEO
• 1. Parkinsonism (2005) / 40 years old 
• 2. Reduced uptake in the left putamen and minimally reduced uptake 
in the left caudate and right putamen (DAT scan December 2005)
• 3. Right hip replacement (July 2009)
• 4. Bilateral STN stimulators inserted (November 2012)
• 5. Medtronic ACTIVA PC box replacement (August 2017)
Present complaints: Painful dyskinesia, dystonia, left leg tremor, 
walking with extreme difficulty, insomnia
Medications: Stalevo 125mg qds and Amantadine 100mg
Case II, Progress
Before HBOT After 20 sessions of HBOT with no other 
intervention
Upper body dyskinesia 30% improvement
Left leg tremor 50% improvement
walking with extreme difficulty & only short 
distance 
30% improvement 
Severe rigidity, full range of motion achieved 
with difficulty
50% improvement
Freezing when walking 50% improvement
Poor quality interrupted sleep Sleeps well 
• Numerous in vivo and in vitro studies confirms that HBOT induces 
neurogenesis 
• Wang XL. et al. [Hyperbaric oxygen promotes the migration and differentiation of endogenous neural 
stem cells in neonatal rats with hypoxic-ischemic brain damage] Zhongguo Dang Dai Er Ke Za
Zhi. 2009;11(9):749–52. [PubMed]
• Zhang XY. et al. The role of beta-catenin signaling pathway on proliferation of rats neural stem cells after 
hyperbaric oxygen therapy in vitro. Cell Mol Neurobiol. 2011;31(1):101–9. doi: 10.1007/s10571-010-
9559-z. [PubMed]
• Milosevic J. et al. Non-hypoxic stabilization of hypoxia-inducible factor alpha (HIF-alpha): relevance in 
neural progenitor/stem cells. Neurotox Res. 2009;15(4):367–80. doi: 10.1007/s12640-009-9043-
z. [PubMed] [Cross Ref]
• Godman CA. et al. Hyperbaric oxygen treatment induces antioxidant gene expression. Ann N Y Acad
Sci. 2010;1197:178–83. doi: 10.1111/j.1749-6632.2009.05393.x. [PubMed]
• Yang YJ. et al. Hyperbaric oxygen induces endogenous neural stem cells to proliferate and differentiate in 
hypoxic-ischemic brain damage in neonatal rats. Undersea Hyperb Med. 2008;35(2):113–29. [PubMed]
• Zhang T. et al. Hyperbaric oxygen therapy improves neurogenesis and brain blood supply in piriform 
cortex in rats with vascular dementia. Brain Inj. 2010;24(11):1350–7. doi: 
10.3109/02699052.2010.504525. [PubMed]
• Gunther A. et al. Reduced infarct volume and differential effects on glial cell activation after hyperbaric 
oxygen treatment in rat permanent focal cerebral ischaemia. Eur J Neurosci. 2005;21(11):3189–94. doi: 
10.1111/j.1460-9568.2005.04151.x. [PubMed]
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Evidence of inflammatory system involvement in Parkinson's disease
Inflammatory factors involved in Parkinson’s disease
Cytokines and other soluble molecules IL-1, IL-2, IL-4, IL-6, IL-10, TNF-, IFN-, TGF-, IL-6, MMP-3, IL-17, and 
IL-18
Pattern recognition receptors (PRRs) TLRs (TLR-1, -2, -3, and -7), NLRs, and complements
Immune cells Microglia, monocyte, NK cell, T-cell, and B cell

Potential benefit of HBOT
Gut-Brain Axis 
• Lewy pathology has been described in 
neurons of the enteric nervous system in 
nearly all Parkinson’s disease (PD) patients 
at autopsy
• The enteric nervous system not only 
contains a variety of functionally distinct 
enteric neurons but also harbors a 
prominent component of glial cells, the so-
called enteric glial cells, which, like 
astrocytes of the central nervous system, 
contribute to support, protect, and 
maintain the neural network
• recently shown that enteric glial cell 
dysfunction occurs in PD.
Combining HBOT with other treatment modalities 
• Nutrition: Ketogenic Diet?
• Optimizing gut microbiome  
• Tailored supplements, vitamins and minerals 
• Cannabidiol
• Low dose naltrexone 
• Near infrared light therapy 
• Repetitive transcranial magnetic stimulation 




• Two studies presented at the 21st International Congress of Parkinson’s 
Disease and Movement Disorders further explored this possibility and 
assessed the effects of oral cannabidiol (CBD) and inhaled cannabis in 
patients with Parkinson’s disease.
• Maureen A. Leehey, MD, Professor of Neurology and Chief of the 
Movement Disorders Division at the University of Colorado in Aurora, 
and colleagues conducted a phase II, open-label, dose-escalation study 
to evaluate the safety and tolerability of CBD (Epidiolex) in Parkinson’s 
disease
• Over a 31-day treatment period, patients received 5-, 7.5-, 10-, 15-, and 
20-mg/kg/day doses of CBD. 
• 13 patients, mean total UPDRS score significantly decreased from 45.9 at 
baseline to 36.4 at the final visit. UPDRS motor score decreased from 
27.3 to 20.3. Mean rigidity from 9.14 to 6.29
• Laurie K. Mischley, ND, PhD, MPH, Associate Clinical Investigator at 
Bastyr University Research Institute in Kenmore, Washington, and 
colleagues evaluated the effect of inhaled cannabis on Parkinson’s 
disease tremor using motion sensors and qualitative interviews.
LDN
• low-dose naltrexone blocks opioid receptors in the brain for few 
hours and creates a “rebound effect,” resulting in up-regulated 
production of the endogenous opioids beta-endorphin and met-
enkephalin, as well as increased expression of opioid receptors
• both endogenous and exogenous opioids immune modulators
• suppress microglial activation via its antagonistic effect on toll-like 
receptor 4 (TLR4), a non-opioid receptor that is found on 
macrophages such as microglia
Neuron Photomodulation-light therapy
Monitoring the progress of PD patients before, during and after 
HBOT
Thank you 
